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The purpose of this study was to investigate Fragile X Syndrome (FXS)-related mechanisms in
schizophrenia, including CGG triplet expansion, FMR1 mRNA, and fragile X mental retardation protein
(FMRP) levels in lymphocytes. We investigated 36 patients with schizophrenia and 30 healthy controls
using Southern blot analysis, mRNA assay, and enzyme-linked immunosorbent assay (ELISA). General
intellectual functions were assessed with the Wechsler Adult Intelligence Scale-III, and the clinical
symptoms were evaluated with the Positive and Negative Syndrome Scale. Results revealed that,
relative to healthy controls, CGG triplet size and FMR1 mRNA were unaltered in patients with
schizophrenia. However, the FMRP level was signiﬁcantly reduced in patients compared with controls.
We found an association between lower FMRP levels, reduced IQ, and earlier illness onset in
schizophrenia. Chlorpromazine-equivalent antipsychotic dose did not correlate with FMRP levels.
These results raise the possibility of impaired translation of FMR1 mRNA, altered epigenetic regulation,
or increased degradation of FMRP in schizophrenia, which may play a role in dysfunctional
neurodevelopmental processes and impaired neuroplasticity.
& 2012 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Fragile X mental retardation protein (FMRP) is an RNA binding
protein, which is abundant in the soma and dendritic spines of
neurons. FMRP is a translational suppressor for several genes
encoding proteins critical for synaptic transmission and plasticity,
such as subunits of glutamate receptors and postsynaptic proteins
(O’Donnell and Warren, 2002; Bear et al., 2008; Rousseau et al.,
2011). The absence of FMRP characterizes fragile X syndrome
(FXS), which is a prevalent form of inherited mental disabilities
(Reiss and Hall, 2007). In FXS, the absence of FMRP is due to the
silencing of the FMR1 gene, which is caused by the expansion of a
CGG trinucleotide repeat (Xq27.3, 4200 repeats in the full
syndrome; 55–200 repeats in premutation carriers) and increased
methylation of the promoter region (O’Donnell andWarren, 2002;
Bear et al., 2008; Rousseau et al., 2011).
There is increasing evidence that FMR1/FMRP is also involved in
the pathogenesis of other disorders, such as premature ovarian
insufﬁciency, fragile X-associated tremor/ataxia syndrome, andd Ltd. All rights reserved.
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ed.hu,autism (Hagerman et al., 2010). Moreover, the spectrum of fragile
X-related disorders might include some forms of schizophrenia,
anxiety, and mood disorders (Bourgeois et al., 2009; Fatemi and
Folsom, 2011). This hypothesis was recently supported by the
observation of Fatemi et al. (2010), who described reduced FMRP
expression in the lateral cerebellum of patients with schizophrenia,
bipolar disorder, andmajor depressive disorder. FMRP is implicated in
glutamatergic and GABA-ergic processes, which are key pathophy-
siological mechanisms of schizophrenia (Fatemi and Folsom, 2011).
The purpose of the present study was to investigate whether
FMRP is decreased in the peripheral blood of patients with
schizophrenia and to assess its relationship with FMR1 mRNA
level. In addition, we explored the relationship between FMRP
expression and clinical characteristics of the patients. We
hypothesized that FMRP is associated with IQ, given that the
absence of this protein is accompanied by a severe cognitive
disability in patients with FXS.2. Methods
2.1. Participants
Participants comprised 36 outpatients with schizophrenia and 30 healthy
volunteers. The control participants were university/hospital employees and their
non-biological relatives and acquaintances. All participants were assessed with
Table 2
CGG triplet size, FMR1 mRNA, and FMRP levels.
Schizophrenia (n¼36) Control (n¼30)
Mean S.D. Range Mean S.D. Range
CGG triplet size 28.4 3.7 17–32 28.7 3.1 19–33
FMR1 mRNA level 1.6 0.4 1–1.9 1.7 0.3 1–1.8
FMRP leveln 78.4 75.3 18–340 124.8 91.0 40–420
FMR1—Fragile X Mental Retardation 1; FMRP—Fragile X Mental Retardation
Protein.
n Z¼3.25, po0.005 (Mann–Whitney U test).
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1996) and the Wechsler Adult Intelligence Scale-III (Wechsler, 1997). Full medical
records were available, and all patients had a previous diagnosis of schizophrenia.
We used the SCID-CV to conﬁrm this diagnosis. The control participants had no
Axis I psychiatric disorders and had a negative family history for psychotic
disorders. Exclusion criteria included neurological disorders, head injury, and
history of psychoactive substance dependence. For the assessment of clinical
symptoms, the Positive and Negative Syndrome Scale (PANSS) was used (Kay
et al., 1987). In the PANSS, positive and negative symptoms are evaluated by 7–7
items (minimum score¼7, maximum score¼49 for positive and negative symp-
toms separately), and general psychopathology symptoms are evaluated by 16
items (minimum score¼16, maximum score¼112). All patients received anti-
psychotic medications at the time of testing (olanzapine: n¼14, risperidone:
n¼11, quetiapine: n¼4, risperidone plus quetiapine: n¼7). Antipsychotic doses
were converted into chlorpromazine equivalents (Woods, 2003). The patients did
not receive any other psychotropic medications at the time of testing. Table 1
summarizes the clinical and demographic characteristics of the participants. The
study was carried out in accordance with the Declaration of Helsinki and was
approved by the local ethics board. All participants gave written informed consent.2.2. Molecular biological measurements
All molecular measurements were based on published standard protocols.
Peripheral blood was drawn from the cubital vein of the participants. CGG repeat
size was determined using Southern blot analysis (Steyaert et al., 2003). We
measured FMR1 mRNA using Affymetrix Quantigene (Vala Sciences Inc., CA) by
adopting the protocol of Tassone et al. (2000). For the quantitative measurement
of FMRP levels, we used a new enzyme-linked immunosorbent assay (ELISA)
method (Iwahashi et al., 2009). This method uses a combination of avian and
murine antibodies, and it is highly sensitive and speciﬁc for FMRP in peripheral
blood lymphocytes. The correlation of this ELISA approach with Western blot
analysis of lymphocyte extracts is r¼0.99 (Iwahashi et al., 2009). Further
advantages of this method are that it is suitable for the quantiﬁcation of FMRP
levels in biologically relevant ranges, speciﬁc for the intact FMRP protein,
applicable in non-transformed cells, and scalable for large sample numbers.
Concentrations of FMRP were determined using SoftMax Pro 4-parameter ﬁt
logistics curve (pM; Iwahashi et al., 2009).3. Results
Table 2 summarizes the results. Given that the variables were
not normally distributed, as revealed by Kolmogorov–Smirnov
tests, we used non-parametric Mann–Whitney U-tests. Patients
with schizophrenia displayed normal CGG triplet size and FMR1
mRNA level. In contrast, the level of FMRP was signiﬁcantly
reduced in patients relative to controls (Table 2). Earlier age at
illness onset and lower IQ were associated with decreased FMRP
levels in patients with schizophrenia (illness onset: Spearman’s
R¼0.59, po0.001; IQ: Spearman’s R¼0.66, po0.001). Regarding
the IQ, a similar trend was observed in healthy controls, but it did
not reach the level of statistical signiﬁcance (Spearman’s R¼0.24,
p¼0.17) (Fig. 1). There was no signiﬁcant difference between
male and female participants (p40.5).Table 1
Demographic and clinical characteristics.
Schizophrenia
(n¼36)
Control
(n¼30)
Male/female 22/14 20/10
Age (years) 35.5 (6.9) 36.4 (8.3)
IQn 97.5 (9.6) 103.3 (8.9)
Age of illness onset (years) 24.0 (4.6) –
PANSS positive 19.7 (5.4) –
PANSS negative 17.8 (6.3) –
PANSS general 46.7 (9.1) –
Antipsychotics (chlorpromazine-
equivalent, mg/day)
460.5 (120.9) –
Data are mean (standard deviation). PANSS—Positive and Negative Syndrome
Scale.
n t(64)¼2.50, po0.05.We conducted a multiple regression analysis to control for age
and gender in patients with schizophrenia (data were log-trans-
formed); this model also included age at illness onset and IQ.
The analysis indicated that illness onset and IQ were signiﬁcant
predictors of the FMRP level (illness onset: bn¼0.43, t(31)¼2.67,
po0.05; IQ: bn¼0.46, t(31)¼3.30, po0.05).
Finally, PANSS scores and the daily chlorpromazine-equivalent
dose of antipsychotics did not correlate with FMRP levels (Spear-
man’s R: 0.2oRo0.2, p40.1).4. Discussion
The results of the present study demonstrated that the
mechanism behind low peripheral FMRP in patients with schizo-
phrenia is different from that observed in FXS. Patients with FXS
display CGG triplet expansion, and decreased FMR1 mRNA and
FMRP, whereas patients with schizophrenia are characterized by
reduced FMRP together with normal CGG triplet size and FMR1
mRNA. This suggests that the dysfunction may be related to
abnormal translation of FMR1mRNA, although the CGG triplet is a
key factor in determining translational efﬁcacy, and it was not
altered in patients. An alternative explanation is that the degra-
dation of FMRP is accelerated in schizophrenia. Future studies
should also take into consideration the potential role of epigenetic
regulations of FMR1 (Sto¨ger et al., 2011).
The most important ﬁnding of the study was that decreased
FMRP was associated with earlier illness onset and lower IQ. This
suggests that reduced FMRP may be related to neurodevelop-
mental changes, neuroplasticity, and cognitive functions. In an
extensive meta-analysis of thousands of cases and controls, it was
conﬁrmed that greater premorbid IQ decrement is associated
with earlier illness onset (Khandaker et al., 2011). In the case of
cross-sectional studies, however, neuropsychological functions
are linked to current IQ instead of to IQ trajectory during the
disease course (Kremen et al., 2008).
Similarly to our previous study (Ke´ri and Benedek, 2011,
2012), we found no signiﬁcant correlation between IQ and FMRP
in healthy controls, although the tendency was similar to that
revealed in patients with schizophrenia. This similar tendency
may suggest that FMRP may be implicated in neurodevelopment
and neuroplasticity underlying the emergence of general cogni-
tive abilities, and it is not disease speciﬁc for schizophrenia.
Previously, we observed similar correlations between visual
functions and FMRP expression in healthy controls (Ke´ri and
Benedek, 2011, 2012), with a special reference to contrast
sensitivity functions disrupted in FXS and schizophrenia
(Slaghuis, 1998; Kogan et al., 2004). In this case, similarly to IQ,
FMRP may be important, even under non-pathological circum-
stances, in the physiological range of expression.
Loat et al. (2006) studied the relationship between FMR1 allele
length and cognitive functions in low ability, control, and high-IQ
children. In males, there was a signiﬁcant negative correlation
Fig. 1. Correlations between IQ and FMRP (fragile X mental retardation protein) in patients with schizophrenia and controls.
T. Kova´cs et al. / Psychiatry Research 210 (2013) 690–693692between allele length, non-verbal ability, and IQ. Mı´nguez et al.
(2009) demonstrated that in premutation carriers, IQ scores tend
to decrease when the number of CGG repeats is higher and the
FMRP values are lower (but see also Franke et al., 1998, 1999). In
patients with schizophrenia, we found a similar relationship
between FMRP and IQ, but in this case, CGG triplet size was
normal.
The most important limitation of the present study is that we
used a correlational approach with a cross-sectional design, and
we cannot establish a ﬁrm causal relationship between the
dependent measures. Therefore, it remains to be conﬁrmed
whether reduced FMRP plays a causal role in schizophrenia and
the associated cognitive deﬁcit. Although we did not ﬁnd a
correlation between FMRP and antipsychotic dose, the results
must be replicated in unmedicated patients. Furthermore, that
illness-onset was correlated with FMRP levels, but current anti-
psychotic dosage was not, could be indicative that long-term
antipsychotic medication may have a greater effect on FMRP
levels. Long-term antipsychotic administration may lead to
decreased IQ, although it can be seen only when unusually high
doses and multiple medications are administered (Hori et al.,
2006). Based on the medical records of our patients, however,
there was no evidence for unusually high antipsychotic doses.
Although FXS exhibits many similarities with autism, its
relationship with psychotic disorders is less convincing. In female
premutation carriers, early studies revealed pronounced schizo-
typal features and lower IQ (Reiss et al., 1988; Freund et al., 1992).
Nicolson et al. (1999) suggested that cytogenetic abnormalities
are increased in cases of childhood-onset schizophrenia, consis-
tent with a model that earlier onset is due to a marked impair-
ment of neurodevelopmental processes. However, the authors did
not conﬁrm the role of fragile-X associated mechanisms (see also
DeLisi et al., 1988; Jo¨nsson et al., 1995; Franke et al., 1996). Others
concluded that mutations in the FMR1 gene do not have a role in
schizophrenia, but it is possible that FMR1 mutations can modify
the clinical appearance of the illness, with a special relevance to
developmental delay (Ashworth et al., 1996). Khin et al. (1998)
described a male psychotic patient who had an FMR1 gene
methylation mosaicism. More recently, Tam et al. (2010) founda copy number variant in cytoplasmic FMR1-interacting protein 1
(CYFIP1) gene in patients with schizophrenia.
The results of our study are consistent with the data indicating
that fragile-X-related mechanisms are not altered at gene and
mRNA levels in schizophrenia. However, a reduced level of FMRP
was associated with lower IQ and earlier illness onset, which may
represent the neurodevelopmental aspects of schizophrenia.Acknowledgments
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